BIC/FTC/TAF

NCT07075146 is a Phase 3 trial comparing Biktarvy (bictegravir plus emtricitabine plus tenofovir alafenamide, made by Gilead) against an older three-drug regimen of doravirine plus tenofovir disoproxil fumarate plus lamivudine in HIV-positive adults who are starting antiretroviral therapy and are already overweight or obese [1]. The clinical question is narrow but commercially loaded. Biktarvy is Gilead's franchise HIV pill, generating $13.4 billion in 2024 revenue and contributing approximately 47% of the company's product sales ($13.4B of $28.75B) [2]. Integrase inhibitors combined with TAF have been linked to weight gain that worries clinicians treating an aging HIV population with rising cardiovascular and metabolic comorbidities [3]. If the older, weight-neutral regimen matches Biktarvy on virologic suppression with less metabolic baggage, prescribing patterns could shift in a growing segment of first-line HIV care. The trial sits at the intersection of two long-running trends: HIV is now a chronic disease managed for decades, and the patient population is increasingly overweight to a degree that drives long-term cardiovascular risk more than viral replication does.

Both regimens in this trial are already approved as components or fixed-dose combinations. Biktarvy received FDA approval in February 2018 and dominates first-line HIV therapy with roughly half of new US prescriptions in recent years per Gilead's filings [2]. Doravirine cleared FDA in 2018 (Merck's Pifeltro and Delstrigo), and the TDF/3TC backbone has been off-patent for years. This is a Phase 3 head-to-head designed not to win approval for either drug but to inform clinical choice in an enriched metabolic-risk population. No FDA breakthrough or fast track designation applies, because this is comparative effectiveness research and not a drug development program. Readout timing depends on enrollment pace, with a 48-week primary virologic endpoint plus longer-tail metabolic secondaries suggesting first results in roughly late 2027 or 2028 if recruitment hits target [1]. The earlier commercial signal will come from Gilead's own switching program, including the bictegravir/lenacapavir versus Biktarvy comparison in virologically suppressed adults (NCT06333808), which is active and reads out sooner [4]. Note that 'franchise defense' for Biktarvy is not about imminent generics. Gilead's Biktarvy patent portfolio runs to approximately 2036 for full generic entry, with a subordinate ViiV settlement patent expiring October 2027 that does not end exclusivity. The real defensive priority is preventing share loss to long-acting injectables like cabotegravir/rilpivirine (Cabenuva, ViiV Healthcare/Janssen) and to Gilead's own next-generation bictegravir/lenacapavir combination.

Biktarvy is three drugs in one pill, each blocking a different step in HIV's life cycle. Bictegravir is an integrase strand transfer inhibitor, called INSTI for short. HIV has to splice its own DNA into the host cell's genome to make new virus, and integrase is the molecular scissors that does the splicing. Bictegravir jams the scissors. Emtricitabine and tenofovir alafenamide are nucleoside and nucleotide reverse transcriptase inhibitors, called NRTIs. HIV is an RNA virus, so before it can integrate it has to copy its RNA into DNA using an enzyme called reverse transcriptase. NRTIs are decoy building blocks: when reverse transcriptase tries to use them, the copying machinery stalls. The mechanism is fully validated. INSTI-based three-drug regimens have been first-line HIV therapy globally since around 2018, with dolutegravir from ViiV (approved 2013) and bictegravir from Gilead (approved 2018) as the two pillars, both following raltegravir as the first-in-class INSTI approved in 2007. The wrinkle this trial probes is metabolic. Cohort studies and randomized trials show that switching from older NNRTI-based regimens, especially efavirenz, to INSTI plus TAF leads to 2 to 5 kg of weight gain on average over a year [3]. The mechanism behind that gain is not fully worked out: TAF concentrates in adipose tissue at higher levels than TDF, INSTIs may affect appetite or adipocyte biology, and some weight increase reflects return-to-health rather than drug toxicity. For HIV-positive adults already obese at diagnosis, the extra kilos drive cardiovascular and diabetes risk that now competes with viral suppression as the clinically dominant long-term concern.

NCT07075146 is a Phase 3 randomized open-label comparison enrolling antiretroviral-naive adults living with HIV who have a body mass index in the overweight or obese range [1]. The trial's specific BMI enrollment threshold (≥25 kg/m² vs ≥30 kg/m²) is not specified in the publicly available enrichment data; the cutoff matters because it determines how metabolically enriched the population actually is and how easily a weight differential could reach significance. The active comparator is doravirine plus tenofovir disoproxil fumarate plus lamivudine, which pairs a non-nucleoside reverse transcriptase inhibitor (NNRTI) with the older tenofovir prodrug that has been linked to less weight gain than TAF. The primary endpoint follows the regulatory template for HIV trials: proportion of participants with HIV-1 RNA below 50 copies per mL at week 48 by the FDA snapshot algorithm. The FDA snapshot algorithm counts any participant who missed their 48-week visit or discontinued treatment as a virologic failure, making it a conservative intent-to-treat measure rather than a best-case efficacy count. This is why snapshot success rates often run several percentage points below per-protocol numbers in the same trial. Secondary endpoints almost certainly include weight change, waist circumference, lipid profile, glucose homeostasis, and bone and renal safety markers, since those are the axes where TAF and TDF, and INSTI versus NNRTI, separate most cleanly. Specific enrollment target, country list, and recruitment status for NCT07075146 could not be independently verified from the enrichment data provided here. The underlying registry record describes an investigator-initiated sponsor rather than Gilead, which carries implications for analysis flexibility and publication independence but also for funding and recruitment pace. Investigator-initiated head-to-head HIV trials with metabolic endpoints have historically taken longer to enroll and read out than industry-sponsored registrational programs, where site networks are pre-built and recruitment is incentivized.

Our model estimates a 38% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 64%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is low on the primary virologic endpoint and high on the secondary metabolic question. Both regimens reliably suppress HIV in treatment-naive adults based on prior trials of each component, so a virologic miss in either arm would be a surprise. The Al-Hayani et al. bifast study of B/F/TAF in ART-naive patients [6] is the most directly relevant naive-population data; the switching study literature [7] supports tolerability but speaks to a different clinical population. The real efficacy risk is that the weight differential between arms ends up smaller than expected, leaving clinicians with no clear winner. Real-world cohorts suggest 1 to 3 kg of separation between TAF-INSTI and TDF-NNRTI regimens at one year [3]. If the trial is underpowered for that effect, a null secondary result gets read as 'both equivalent' and Biktarvy keeps its market share by default. Safety risk cuts in both directions. TDF carries known bone density loss and renal tubular toxicity that TAF was specifically designed to address, so the doravirine arm could lose on those safety markers even if it wins on weight. Bictegravir plus TAF carries the documented weight gain signal and emerging questions from recent meta-analyses about INSTI-associated cardiovascular events. Execution risk is the biggest unknown. Most newly diagnosed HIV patients in 2026 are started on an INSTI-based regimen at their first specialist visit and may decline randomization to an older NNRTI. Commercial risk is asymmetric for Gilead but, critically, the larger long-term threat to Biktarvy's first-line share is not weight concerns from this trial but the shift toward long-acting injectables. Cabotegravir/rilpivirine (Cabenuva) from ViiV Healthcare/Janssen removes the daily pill burden entirely and is gaining first-line share in patients with stable insurance and clinic access for monthly or bimonthly dosing. A negative weight result here matters at the margin; the injectable shift matters at the trajectory level.

Worth watching for the weight signal, not the virologic readout. The clinically interesting question is whether doravirine plus TDF plus 3TC produces meaningfully less weight gain than Biktarvy in patients who are already overweight, and whether that differential is large enough to flip prescribing in a subpopulation that represents a growing share of HIV-positive adults in high-income countries. A 3 kg or greater separation at 48 weeks paired with non-inferior virologic suppression would be the trial-defining signal. Context worth noting: many US clinics are already preferentially using dolutegravir-based regimens (rather than bictegravir) in metabolically high-risk patients based on existing cohort data, so this trial's specific relevance is to Biktarvy's residual share in that segment rather than to the INSTI class broadly. The bigger Gilead story to track in parallel is the bictegravir/lenacapavir switch trial (NCT06333808), which tests whether Gilead can defend its HIV franchise by moving from Biktarvy to a longer-acting two-drug regimen [4]. The franchise-defense framing is not about generics - Biktarvy patents run to roughly 2036 - but about share loss to long-acting injectables like Cabenuva and to next-generation Gilead regimens. Biktarvy contributed $13.4 billion in 2024 revenue (approximately 47% of Gilead's $28.75B product sales) [2], so any erosion in first-line market share matters for the stock. Check back in late 2027 for first NCT07075146 results, and watch CROI and IAS mid-cycle updates in 2026 and 2027 for enrollment progress or interim metabolic data. Gilead's quarterly earnings calls will signal whether real-world prescribing is already moving on weight concerns ahead of trial readout, which is the leading indicator for whether this Phase 3 changes practice or confirms it.